Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical diseaseThe blood-brain barrier in cortical multiple sclerosis lesionsBlood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis.Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity.The blood-brain barrier and its role in immune privilege in the central nervous system.Functions of lipid raft membrane microdomains at the blood-brain barrier.The blood-brain barrier in multiple sclerosis: microRNAs as key regulators.Molecular alterations of the blood-brain barrier under inflammatory conditions: The role of endothelial to mesenchymal transition.Morphogens and blood-brain barrier function in health and disease.In Vitro and Ex Vivo Model Systems to Measure ABC Transporter Activity at the Blood-Brain Barrier.Altered blood-brain barrier transport in neuro-inflammatory disorders.Retinoic acid induces blood-brain barrier development.Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.Protective effects of peroxiredoxin-1 at the injured blood-brain barrier.Blood-brain barrier leakage after status epilepticus in rapamycin-treated rats II: Potential mechanisms.GM-CSF promotes migration of human monocytes across the blood brain barrier.Enhanced microglial pro-inflammatory response to lipopolysaccharide correlates with brain infiltration and blood-brain barrier dysregulation in a mouse model of telomere shortening.Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis.Interferon-beta prevents cytokine-induced neutrophil infiltration and attenuates blood-brain barrier disruption.Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation.Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy.The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammationActivation of the innate immune system is evident throughout epileptogenesis and is associated with blood-brain barrier dysfunction and seizure progressionMycobacteria employ two different mechanisms to cross the blood-brain barrierInflammation of the choroid plexus in progressive multiple sclerosis: accumulation of granulocytes and T cellsSpecialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunctionLiver X Receptor Alpha Is Important in Maintaining Blood-Brain Barrier FunctionUtility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals
P50
Q27023953-E968A001-9834-4EB1-ACB7-99B6329C6E7FQ28296839-00F9A3EB-32E1-4C7F-971E-D7A6BD777027Q34436332-100EC512-0087-44E6-9A73-464283438535Q34554148-D8BD56B4-4084-4938-803F-3AEC6933EAD9Q35166289-20BF2784-E97F-42FA-979F-F7AECCB03396Q37502742-798380E8-2E1D-4F9E-A9F7-F939C2A5A509Q38329179-F9F080AE-27EC-429E-BFDB-D2B19024D3EDQ38614183-D1E707A2-7D3C-44D1-A799-47956709CFF3Q38824367-5587037A-5E94-402A-9E0B-1F2BAD6E10A4Q38925068-72473BA9-CA2E-462E-AF7C-5EDCA35E8E9FQ39041653-0B400136-654C-44CC-B974-B9B7D1724E4BQ39205654-E3166C2B-DC5F-492A-B0BD-43139EC4BE3AQ39597830-0038C6C4-74F7-459D-8C81-34753BDEABA6Q39985913-767C2390-71DC-40CC-AC81-719ED1A89B61Q40183907-BB688F7B-6D40-4187-B8BF-EBA428C9A002Q41254947-3DBF97D4-FAB0-418D-A27A-D0FAFAE11393Q41872866-D6F3A5D4-157F-40CA-AD1C-1AD0BC7D2F9CQ46622490-7B87D795-7581-46DA-A0F9-ACA79095BA9CQ46848816-45DC51A9-833D-465F-AFC6-1307EA96F924Q48198774-E0CE9ACA-9A39-468C-BA46-4458198C0BFDQ48435795-69EBB6AB-43D5-41C6-AE26-2DE80CB4D85DQ48501239-5FC9E9E6-0660-4F82-B5AF-4166371B322CQ48678622-959F9137-0D3F-48C1-BB18-5D500C3626B8Q48797548-35FE86EA-C4A5-4AFD-B4AE-337CD74D09A9Q57076406-27592130-4ACA-4EB6-91F8-3809B016B326Q57159315-5B21A5AE-8803-41B7-BF09-FA738CE7D8E9Q59497552-9CB69EB4-33A4-43AB-919B-5DA32D6CD5FDQ89514435-76AFAC3C-94E3-4D6E-901F-84C04EF569CEQ91525055-7B6F98DF-4BD5-4784-8F4D-BDD3CC453E0FQ92650614-2981CC27-CD27-4FAE-B305-E9412B5FFF8DQ94515440-78121A9A-DA9C-49C6-9879-8AC5F2D26F06
P50
description
researcher
@en
wetenschapper
@nl
name
Helga E de Vries
@en
Helga E de Vries
@nl
type
label
Helga E de Vries
@en
Helga E de Vries
@nl
prefLabel
Helga E de Vries
@en
Helga E de Vries
@nl
P21
P31
P496
0000-0001-7904-7124